Back to results
US 2025/0051340 A1Published application
Triazolone derivative salt as neutrophil elastase inhibitor
AssigneeChiesi Farmaceutici S.p.A.
InventorsGabriele AMARI, Carmelida CAPALDI, Elisabetta ARMANI
Life of this patent
Estimating the term…
Abstract
The present invention generally relates to a novel triazolone derivative salt particularly useful as neutrophil elastase inhibitor and to its use as a medicament. The present invention also relates to pharmaceutical compositions comprising the novel triazolone derivative salt and one or more pharmaceutically acceptable carriers and/or excipients thereof and to their use as medicament.
Claims19
1:
- The compound (2-{5-Cyano-2-[(R)-6-methoxycarbonyl-7-methyl-3-oxo-8-(3-trifluoromethyl-phenyl)-2,3,5,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrimidin-5-yl]-phenyl}-ethyl)-trimethyl-ammonium hemi-pamoate of formula (I)
2:
- A pharmaceutical composition comprising the compound of formula (I) of claim 1 and one or more pharmaceutically acceptable carriers and/or excipients.
3:
- A pharmaceutical composition according to claim 2, formulated in form of a dry powder.
4-5. (canceled)
6:
- A method for the prevention and/or treatment of an inflammatory or obstructive respiratory disease, comprising administering to a subject in need thereof an effective amount of the compound of formula (I) according to claim 1.
7:
- A method for the prevention and/or treatment of an inflammatory or obstructive respiratory disease, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition according to claim 2.
8:
- The method according to claim 6, wherein the inflammatory or obstructive respiratory disease is selected from the group consisting of asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis, chronic bronchitis, lung fibrosis, idiopathic pulmonary fibrosis, pneumonia, acute respiratory distress syndrome (ARDS), pulmonary emphysema, smoking-induced emphysema and cystic fibrosis.
9:
- The method according to claim 7, wherein the inflammatory or obstructive respiratory disease is selected from the group consisting of asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis, chronic bronchitis, lung fibrosis, idiopathic pulmonary fibrosis, pneumonia, acute respiratory distress syndrome (ARDS), pulmonary emphysema, smoking-induced emphysema and cystic fibrosis.
10:
- A process for the preparation of the compound of formula (I) according to claim 1, comprising:
- (1) dissolving in water a water-soluble salt of (2-{5-cyano-2-[(R)-6-methoxycarbonyl-7-methyl-3-oxo-8-(3-trifluoromethyl-phenyl)-2,3,5,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrimidin-5-yl]-phenyl}-ethyl)-trimethyl-ammonium of formula (II):
- wherein X− is an organic or inorganic anion, to obtain a first solution, and
- (2) mixing said first solution with a second solution of a pamoate salt of formula (III):
- wherein Y+ is an alkaline or alkaline earth metal cation
2 more elements
11:
- A process according to claim 10, wherein the molar ratio between the compound of formula (II) and the pamoate salt of formula (III) is 2:1.
12:
- A process according to claim 10, wherein X− is bromide.
13:
- A process according to claim 10, wherein X− is methanesulfonate.
14;
- A process according to claim 10, wherein X− is propionate.
15:
- A process according to claim 10, wherein Y+ is sodium or potassium.
16:
- A process according to claim 11, wherein X− is bromide.
17:
- A process according to claim 11, wherein X− is methanesulfonate.
18:
- A process according to claim 11, wherein X− is propionate.
19:
- A process according to claim 11, wherein Y+ is sodium or potassium.
20:
- A method for the prevention and/or treatment of an inflammatory or obstructive respiratory disease, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition according to claim 3.